Detailed company information
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q1Released: Feb 09, 2026
Earnings Transcript for 2025 - Q4Released: Nov 25, 2025
Earnings Transcript for 2025 - Q3Released: Aug 12, 2025
Earnings Transcript for 2025 - Q2Released: May 13, 2025
Earnings Transcript for 2025 - Q1Released: Feb 12, 2025
Earnings Transcript for 2024 - Q4Released: Dec 23, 2024
Earnings Transcript for 2024 - Q2Released: Aug 06, 2024
Earnings Transcript for 2024 - Q1Released: Feb 07, 2024
Earnings Transcript for 2023 - Q4Released: Nov 27, 2023
Earnings Transcript for 2023 - Q3Released: Aug 08, 2023
Earnings Transcript for 2023 - Q2Released: May 09, 2023
Earnings Transcript for 2023 - Q1Released: Feb 07, 2023
Earnings Transcript for 2022 - Q4Released: Nov 28, 2022
Earnings Transcript for 2022 - Q3Released: Aug 09, 2022
Earnings Transcript for 2022 - Q2Released: May 10, 2022
Earnings Transcript for 2022 - Q1Released: Feb 09, 2022
Earnings Transcript for 2021 - Q4Released: Nov 24, 2021
Earnings Transcript for 2021 - Q3Released: Aug 12, 2021
Earnings Transcript for 2021 - Q2Released: May 13, 2021
Earnings Transcript for 2021 - Q1Released: Feb 12, 2021
Earnings Transcript for 2020 - Q4Released: Dec 28, 2020
Earnings Transcript for 2020 - Q3Released: Aug 09, 2020
Earnings Transcript for 2020 - Q2Released: May 08, 2020
Earnings Transcript for 2020 - Q1Released: Feb 07, 2020
Dafinchi
